汪维鹏

 

 

2.jpg

 

姓  名:汪维鹏

       称:副教授

联系电话:0512-65883761

电子邮箱:wangweipeng@suda.edu.cn

办公地址:云轩楼1339

 

 个人简介:

一、学习工作经历

1、学历背景:

1997.92002.7 中国药科大学中药药理学,本科

2002.92007.6 中国药科大学药物分析学,博士

2、工作经历:

2007.82010.7 苏州大学药学院药物分析教研室,讲师

2008.92011.8 苏州大学医学生物技术研究所,博士后

2010.8至今      苏州大学药学院药物分析学系,副教授

2013.6-2014.6  美国加州大学戴维斯分校,博士后

 

二、研究方向

1)肿瘤免疫与药物处置

2)微小RNA药物研究 

(3)肿瘤个体化治疗

 

三、主要研究成果

主持国家自然科学基金项目2项;以第一或通讯作者发表SCI论文21篇,中文核心期刊论文8篇,ISTP国际会议论文7篇;获中国免疫学会青年学者奖、江苏省科技进步三等奖、2011年度军队医疗成果二等奖 

 

1、论文*通讯作者)

1 Chen Q#, Mao Y#, Meng FY, Wang L, Zhang HJ, Wang WP*, Hua D*. Rs7911488 modified the efficacy of capecitabine-based therapy in colon cancer through altering miR-1307-3p and TYMS expression. Oncotarget, accepted. IF2017: 5.168; 一区)

2 Chen Q#, Meng FY#, Wang L, Mao Y, Zhou H, Hua D, Zhang HJ, Wang WP*. A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients. Scientific Reports, accepted. IF2017: 4.259; 二区)

3 Tao LH#, Zhou XR#, Li FC, Chen Q, Meng FY, Mao Y, Li R, Hua D, Zhang HJ, Wang WP*, Chen WC*. A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer. Cancer Immunol Immunother, 2017 Mar;66(3):309-318. IF2017: 4.711; 二区)

4 Zhou XR#, Mao Y#, Zhu JJ, Meng FY, Chen Q, Tao LH, Li R, Fu FQ, Liu CP, Hu YJ, Wang WP*, Zhang HJ, Hua D, Chen WC, Zhang XG. TGF-β1 promotes colorectal cancer immune escape by elevating B7-H3 and B7-H4 via the miR-155/miR-143 axis. Oncotarget. 2016 Oct 11;7(41):67196-67211. IF2016: 5.008; 一区)

5 Tang R#, Qi Q#, Wu R, Zhou X, Wu D, Zhou H, Mao Y, Li R, Liu C, Wang L, Chen W, Hua D, Zhang H, Wang WP*. The polymorphic terminal-loop of pre-miR-1307 binding with MBNL1 contributes to colorectal carcinogenesis via interference with Dicer1 recruitment. Carcinogenesis, 2015 Aug;36(8):867-75. IF2015: 5.334; 二区)

6 Wang WP#, Ho PY#, Chen QX#, Addepalli B, Limbach PA, Li MM, Wu WJ, Jilek JL, Qiu JX, Zhang HJ, Li T, Wun T, White RD, Lam KS, Yu AM*. Bioengineering novel chimeric microRNA-34a for prodrug cancer therapy: High-yield expression and purification, and structural and functional characterization. J Pharmacol Exp Ther. 2015 Aug;354(2):131-41. IF2015: 3.972; 二区)

7 Wang WP, Li F, Mao Y, Zhou H, Sun J, Li R, Liu CP, Chen WC, Hua D*, Zhang XG*. A miR-570 binding-site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma. Hum Genet. 2013 Jun;132(6):641-8. IF2013: 4.633; 二区)

8Wang WP#, Sun J#, Li F, Li R, Gu YP, Liu CP, Yang P, Zhu M, Chen LJ, Tian WY, Zhou H, Mao Y, Zhang L, Jiang JT, Wu CP, Hua D, Chen WC, Lu BF, Ju JF*, Zhang XG*. A frequent somatic mutation in CD274 3’-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding. Hum Mutat, 2012 Mar;33(3):480-4.IF2012: 5.686; 二区)

 

2、课题

1)国家自然科学基金 (81270031)负性协同刺激分子B7-H1 基因变异在胃癌发生发展过程中的作用机制研究2013-2016,主持。

2)国家自然科学基金 (30901360):负性协同刺激分子B7-H1在胃癌组织中表达的调节机制研究,2010-2012,主持。

 

3、著作

1)《SNP检测技术与个体化药物治疗》(副主编),苏州大学出版社,2015 

2)《药物分析实验教程》(副主编),合肥工业大学出版社出版,2009